Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “ERBB2 Gene Amplification”

63 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 63 results

Testing effectiveness (Phase 2)UnknownNCT05135715
What this trial is testing

RC48-ADC in Advanced Melanoma Subjects With HER2 Variant (Mutation, Amplification, Overexpression)

Who this might be right for
Melanoma, Stage IIHER2-positiveAdvanced Melanoma
RemeGen Co., Ltd. 50
Testing effectiveness (Phase 2)WithdrawnNCT05041972
What this trial is testing

ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02)

Who this might be right for
HER2 Mutation-Related TumorsHER2 Amplified Solid Tumors
Ambrx, Inc.
Large-scale testing (Phase 3)Looking for participantsNCT05786716
What this trial is testing

DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations

Who this might be right for
Haematological MalignancyColorectal NeoplasmsUrinary Bladder Neoplasm+8 more
Cancer Research UK 30
Not applicableStudy completedNCT01066507
What this trial is testing

Detection of Amplification of Her2 Fluorescent in Situ Hybridization (FISH) in Breast Tissue Sections

Who this might be right for
Breast Cancer
Applied Spectral Imaging Ltd. 126
Testing effectiveness (Phase 2)Study completedNCT00356811
What this trial is testing

Lapatinib Combined With Paclitaxel For Patients With First-Line ErbB2-Amplified Metastatic Breast Cancer

Who this might be right for
Neoplasms, Breast
GlaxoSmithKline 57
Testing effectiveness (Phase 2)Active Not RecruitingNCT02314481
What this trial is testing

Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity

Who this might be right for
Non-small Cell Lung Cancer
University College, London 50
Testing effectiveness (Phase 2)UnknownNCT03225937
What this trial is testing

Evaluation of Trastuzumab in Combination With Lapatinib or Pertuzumab in Combination With Trastuzumab-Emtansine to Treat Patients With HER2-positive Metastatic Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer
Fondazione del Piemonte per l'Oncologia 54
Testing effectiveness (Phase 2)Looking for participantsNCT06413745
What this trial is testing

Phase II Clinical Study of SHR-A1811 in Patients With HER2 Expression / Amplification of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Cancer

Who this might be right for
HER2 Expression / Amplification in Patients With Biliary Tract Cancer
Jiangsu HengRui Medicine Co., Ltd. 65
Testing effectiveness (Phase 2)UnknownNCT05016544
What this trial is testing

Inetetamab in Combination With Pyrotinib in HER2 Mutant or Amplified Advanced Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Sun Yat-sen University 48
Testing effectiveness (Phase 2)Active Not RecruitingNCT04439110
What this trial is testing

Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more
National Cancer Institute (NCI) 38
Testing effectiveness (Phase 2)Looking for participantsNCT04879329
What this trial is testing

Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

Who this might be right for
Urothelial Carcinoma
Seagen, a wholly owned subsidiary of Pfizer 372
Testing effectiveness (Phase 2)WithdrawnNCT05512182
What this trial is testing

Efficacy of Triplet Combination With Pembrolizumab, Neratinib, and Paclitaxel as a Second Line Treatment in Recurrent/Advanced Gastric Cancer Having Somatic Human Epidermal Growth Factor Receptor Family (EGFR, HER2, HER3, HER4) Mutations or HER2 Amplification/Overexpression

Who this might be right for
Recurrent/Advanced Gastric Cancer
Yonsei University
Testing effectiveness (Phase 2)Study completedNCT03365882
What this trial is testing

S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery

Who this might be right for
Colon AdenocarcinomaERBB2 Gene AmplificationRectal Adenocarcinoma+16 more
SWOG Cancer Research Network 240
Testing effectiveness (Phase 2)Ended earlyNCT00479856
What this trial is testing

Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer

Who this might be right for
Relapsed Breast CancerNeoplasms, Breast
GlaxoSmithKline 9
Not applicableUnknownNCT03947736
What this trial is testing

Dynamic Monitoring of HER2 and ctDNA Specific Mutations in Patients With Recurrent or Metastatic Breast Cancer by Digital PCR

Who this might be right for
Recurrent or Metastatic Breast Cancer
Chinese Academy of Medical Sciences 200
Testing effectiveness (Phase 2)Study completedNCT03783936
What this trial is testing

Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas

Who this might be right for
Gastric AdenocarcinomaEsophageal AdenocarcinomaMetastasis+1 more
Ashwin Somasundaram 18
Testing effectiveness (Phase 2)Study completedNCT01828021
What this trial is testing

Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast Cancer

Who this might be right for
Breast Cancer
MacroGenics 25
Not applicableLooking for participantsNCT06813456
What this trial is testing

Implementation of Solid Digital PCR to Support Gold-standard Methods for Evaluation of HER2 Amplification Status: Focus on HER2-low Subtype

Who this might be right for
Breast Cancer
IRCCS Azienda Ospedaliero-Universitaria di Bologna 234
Testing effectiveness (Phase 2)UnknownNCT04215159
What this trial is testing

Trastuzumab Biosimilar (Samfenet®) Plus Treatment of Physician's Choice (TPC) in Patients With HER2-positive Solid Tumor

Who this might be right for
HER-2 Protein OverexpressionHER-2 Gene Amplification
Jin-Hee Ahn 42
Testing effectiveness (Phase 2)Study completedNCT03613168
What this trial is testing

Trastuzumab in HER2-positive Biliary Tract Cancer

Who this might be right for
CholangiocarcinomaBiliary Tract CancerHER-2 Protein Overexpression+1 more
Changhoon Yoo 4
Load More Results